Liver Metabolism and Nonalcoholic Fatty Liver Disease
Abstr. due: 30.11.2015
Dates: 22.03.15 — 27.03.15
Organizing comittee e-mail: firstname.lastname@example.org
Organizers: Intercept Pharmaceuticals, Inc., Regeneron Pharmaceuticals, Inc. and Takeda Pharmaceutical Company Limited
Abnormalities in hepatic intermediary metabolism are common in obesity and are a significant source of morbidity and mortality in obese people. For example, nonalcoholic fatty liver disease (NAFLD) affects over 25% of the US population and has become the most common cause of liver failure and transplantation. NAFLD is also linked to the development of major metabolic diseases such as type 2 diabetes and cardiovascular diseases. Despite the central role of the liver in whole-body energy metabolism and its contribution to disease development, there are literally no dedicated meetings that focus on the cellular and mechanistic aspects of the regulation of liver metabolism. This meeting will bring together experts, both basic scientists and clinicians, across diverse fields including biochemistry, cell biology, genetics, hepatology, nutrition, physiology and virology to exclusively focus on the liver and bridge a translational divide. Meeting themes will center on regulation of hepatic energy metabolism, crosstalk between the liver and different organs and cell types and how alterations in macronutrient metabolism contribute to disease etiology. The objectives of this conference are to: 1) Expose scientists across diverse disciplines to different aspects of hepatic metabolism and NAFLD development; 2) Find synergies in research efforts to expedite our understand hepatic energy metabolism; and 3) Explore emerging metabolic targets for therapeutic interventions to prevent or alleviate NAFLD and related comorbidities.
Conference Web-Site: http://www.keystonesymposia.org/index.cfm?e=web.Meeting.Program&meetingid=1353